Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.36 |
| ▸ | PTGER2 | P43116 | 14/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.33 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.33 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.33 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.33 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4125804 | 0.93 | NAMPT (0.36) | NAMPTPTGER2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL4131198 | 0.93 | NAMPT (0.39) | NAMPTPTGER2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL4123658 | 0.91 | TAS2R14 (0.35) | NAMPTPTGER2TAS2R14 | |
| SCHEMBL4135426 | 0.91 | NAMPT (0.36) | NAMPTPTGER2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL4127061 | 0.91 | SLC16A3 (0.34) | — | |
| SCHEMBL4135632 | 0.88 | PTGS2 (0.32) | NAMPT | |
| SCHEMBL3695801 | 0.88 | HTR2C (0.38) | NAMPTPTGER2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL4126972 | 0.87 | NAMPT (0.36) | NAMPTPTGER2TAS2R14ABCC9ABCC8 | |
| SCHEMBL3695804 | 0.87 | ABCC9 (0.34) | NAMPTPTGER2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL4126102 | 0.86 | NAMPT (0.37) | NAMPTPTGER2CHRNB2CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | NAMPT 2129/4885PTGER2 1424/4885CHRNB2 4275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.